BioVaxys Technology Corp. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation…
BioVaxys Technology Corp. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation…
SAN FRANCISCO, CALIFORNIA / ACCESSWIRE / January 13, 2025 / TheraVac Biologics (TheraVac), a company developing innovative immunotherapies for neurological…
Halifax, Nova Scotia--(Newsfile Corp. - January 13, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is…
SurVaxM is the first drug product to be produced in UI Pharmaceuticals new facilityUI Pharmaceuticals is looking forward to supporting…
NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target…
Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis…
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology…
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…
Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential…